Calcitonin-gene related peptide antagonists use in pregnancy and lactation: a brief safety review

Guest Author 01/11/2025

Calcitonin gene-related peptide (CGRP) therapies are the first medications developed specifically for migraine prevention. What is the latest evidence for their use and safety in pregnancy and lactation? By John Wilks BPharm (USyd), FAdPha, Prof Honours – Clinical Pharmacy (UTAS), FANZCAP (Surg., PeriopMed), Consultant Pharmacist, Credentialled Clinical Pharmacist, Norwest Private Hospital Learning objectives After completing

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

This web site is intended for Australian pharmacy professionals and is not a substitute for independent professional advice. Information and interactions contained in this website are for information purposes only and are not intended to be used to diagnose, treat, cure or prevent any disease. Further the accuracy, currency and completeness of the information available on this web site cannot be guaranteed. APPco Pty Ltd, its affiliates and their respective servants and agents do not accept any liability for any injury, loss or damage incurred by use of or reliance on the information made available via or through ajp.com.au whether arising from negligence or otherwise.

Have questions? Search our Help Section

View the AJP website help section

MENU

ajp.com.au

Tags

Hi there! 👋 Looks like you’re not logged in.